Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 13,471 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: cGVHD Clear all
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02105974
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate/Vilanterol, Vilanterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
1,621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
17
States / cities
Riverside, California • Sunset, Louisiana • Saint Charles, Missouri + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 22, 2026, 4:59 AM EDT
Active, not recruiting Phase 3 Interventional

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

NCT06383390
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Interventions
Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
204
States / cities
Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 159 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Chronic Dietary Grape Seed Extract Supplementation on Aortic Stiffness and Hemodynamic Responses to Exercise in Obese Males

NCT04465110
View directory record Official record
Conditions
Obesity Adult Onset
Interventions
Grape Seed Extract
Dietary Supplement
Lead sponsor
California Baptist University
Other
Eligibility
18 Years to 29 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Riverside, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 22, 2026, 4:59 AM EDT
Completed No phase listed Observational

The Application of Performance Improvement Principles to the Patient Throughput Process in an Adult Outpatient Pain Treatment Clinic

NCT00888420
View directory record Official record
Conditions
Chronic Pain
Interventions
Performance Improvement Measures
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
1,221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 21, 2015 · Synced Oct 22, 2026, 4:59 AM EDT
Active, not recruiting Phase 2 Interventional

Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants

NCT05364762
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary Myelofibrosis
Interventions
Cyclophosphamide, Itacitinib, Peripheral Blood Stem Cell Transplantation, Quality-of-Life Assessment, Tacrolimus
Drug · Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Up to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 22, 2026, 4:59 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

NCT05056727
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Hyperkalemia
Interventions
Sodium Zirconium Cyclosilicate (SZC), Placebo, Lisinopril, Valsartan, Irbesartan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
42
States / cities
Surprise, Arizona • Tucson, Arizona • Canyon Country, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 22, 2026, 4:59 AM EDT
Recruiting Phase 2 Interventional

Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Failing One Prior Therapy With a Second Generation Tyrosine Kinase Inhibitor or Asciminib

NCT06817720
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
olverembatinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 3 Interventional

Advanced eHealth for Chronic Obstructive Pulmonary Disease (COPD) in Colorado

NCT01044927
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Integrated Care, Standard Therapy
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Does a Mainstream Summer Camp Experience Improve Pediatric Kidney Patients' Physical Fitness and Self Concept?

NCT02803541
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
12 day mainstream summer camp experience
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
8 Years to 17 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Claryville, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 22, 2026, 4:59 AM EDT
Completed No phase listed Observational

To Study the Prevalence of Insomnia in Geriatric COPD Patients Who Are Enrolled in a Pulmonary Rehabilitation Program.

NCT00346554
View directory record Official record
Conditions
COPD, Sleep Disorders
Interventions
Not listed
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
60 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Oct 22, 2026, 4:59 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

NCT02384954
View directory record Official record
Conditions
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma
Interventions
Rituximab, N-803
Biological
Lead sponsor
Altor BioScience
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
4
States / cities
Minneapolis, Minnesota • St Louis, Missouri • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 22, 2026, 4:59 AM EDT
Recruiting Not applicable Interventional

Short-term Spinal Stimulation Effects in Cerebral Palsy

NCT07826494
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Spinal Stimulation, Treadmill Walking
Device · Other
Lead sponsor
University of Washington
Other
Eligibility
4 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 22, 2026, 4:59 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

NCT04502394
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Interventions
KRT-232, acalabrutinib
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Goshen, Indiana • Cincinnati, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects

NCT02103894
View directory record Official record
Conditions
Alzheimer's Disease (AD), Parkinson's Disease (PD), Chronic Traumatic Encephalopathy (CTE), Progressive Supranuclear Palsy (PSP), Frontal Temporal Dementia (FTD), Pick's Disease, Tauopathies
Interventions
[18F]T807 ([18F]MNI-777)
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 22, 2026, 4:59 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT

NCT03689894
View directory record Official record
Conditions
Chronic Graft-versus-host-disease
Interventions
Ibrutinib, Rituximab
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis

NCT02872285
View directory record Official record
Conditions
Psoriasis
Interventions
Drug: LYC-30937-EC, Placebo
Drug
Lead sponsor
Lycera Corp.
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Carmel, Indiana • Andover, Massachusetts • Fridley, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 22, 2026, 4:59 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies

NCT01799889
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Non-FL Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma
Interventions
Entospletinib MM, Entospletinib SDD
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
46
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Not applicable Interventional

Wellness Through Mobile Health

NCT04640090
View directory record Official record
Conditions
Musculoskeletal Diseases, Chronic Pain, Anxiety Disorders, Depression
Interventions
Smartphone app (Wysa)
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Not applicable Interventional

Characteristics and Clinical Implications of a Clinical Decision Support System

NCT03295097
View directory record Official record
Conditions
Chronic Illness, Opioid Use, Palliative Care
Interventions
Clinical Decision Support System
Other
Lead sponsor
Hospice of Henderson County, Inc.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
New York, New York • Flat Rock, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Not applicable Interventional

Up, Down, and All Around: Evaluating Mobility Devices for Young Children With Developmental Disabilities and Delays

NCT06591559
View directory record Official record
Conditions
Down Syndrome, Gross Motor Delay, Cerebral Palsy
Interventions
Permobil Explorer Mini, Portable Mobility Aid for Children (PUMA)
Device
Lead sponsor
University of Washington
Other
Eligibility
12 Months to 60 Months
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 22, 2026, 4:59 AM EDT
Completed No phase listed Observational

Comparative Outcome Measures of Patients Receiving Acute Renal ThErapy Study

NCT04912024
View directory record Official record
Conditions
End Stage Kidney Disease, End Stage Renal Disease, Acute Kidney Injury
Interventions
Intermittent Renal Replacement Therapy using the Tablo Hemodialysis System, Intermittent Renal Replacement Therapy using Conventional Hemodialysis Systems
Device
Lead sponsor
Outset Medical
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Timeline
2021 – 2022
U.S. locations
2
States / cities
Orlando, Florida • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Oct 22, 2026, 4:59 AM EDT
Recruiting Phase 2 Interventional

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

NCT06815003
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Graft Versus Host Disease, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Melphalan, Multigated Acquisition Scan, Questionnaire Administration, Tacrolimus, Vedolizumab
Procedure · Drug · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Early Phase 1 Interventional

Feasibility of Near-infrared Spectroscopy to Measure Cortical Pain Pathway (Brain) Activation During Dry Needling

NCT04170803
View directory record Official record
Conditions
Shoulder Pain, Chronic Pain, Musculoskeletal Injury
Interventions
Dry Needling, Sham Dry Needling
Device · Other
Lead sponsor
Army-Baylor University Doctoral Program in Physical Therapy
Other
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 22, 2026, 4:59 AM EDT
Completed Phase 2 Interventional

A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary Disease

NCT00774761
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
fluticasone propionate/formoterol fumarate, fluticasone propionate, formoterol fumarate
Drug
Lead sponsor
Dey
Industry
Eligibility
40 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
San Diego, California • Panama City, Florida • Madisonville, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Oct 22, 2026, 4:59 AM EDT